News
Venclexta has also been granted five Breakthrough Therapy Designations by the FDA, including two for previously untreated AML. Venclexta/Venclyxto is being developed by AbbVie and Roche.
Roche Holding AG RHHBY announced new data from the phase III MURANO study on Venclexta/Venclyxto (venetoclax) in patients with previously treated chronic lymphocytic leukemia (CLL) at the American ...
The FINANCIAL — Roche announced on April 12 that the U.S. Food and Drug Administration (FDA) granted accelerated approval to Venclexta (venetoclax) for the treatment of people with chronic ...
After establishing Venclexta as a treatment for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML), AbbVie and Roche were hoping to demonstrate the med's promise in a subset of mul ...
Venclexta is being developed by AbbVie and Genentech, a member of the Roche Group. It is jointly commercialized by the companies in the United States and commercialized by AbbVie outside of the ...
Large-cap biopharmaceuticals AbbVie (ABBV 1.30%) and Roche (RHHBY 0.24%) announced last week that the U.S. Food and Drug Administration (FDA) had granted their joint effort, Venclexta, a ...
Dec 4 (Reuters) - Roche Holding AG: Dec 4 (Reuters) - Roche Holding AG: Skip to main content. Exclusive news, data and analytics for financial market professionals Learn more about Refinitiv.
Venclexta, the AbbVie- and Roche-developed treatment for leukemia, may not prove effective for another form of blood cancer, multiple myeloma. AbbVie reported Friday morning that data from a Phase ...
Roche (RHHBY) gains an FDA nod for the sNDA of its leukemia drug, Venclexta, in combination with Gazyva for the treatment of previously untreated chronic lymphocytic leukemia.
June 4 (Reuters) - ROCHE HOLDING AG: June 4 (Reuters) - ROCHE HOLDING AG: Skip to main content. Exclusive news, data and analytics for financial market professionals Learn more about Refinitiv.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results